Why is Mankind Pharma falling/rising?

Recent Price Movement and Market Performance

The stock has been under pressure for the past week, registering a 3.34% loss while the Sensex remained virtually flat with a marginal 0.02% gain. Over the past month, Mankind Pharma’s shares have declined by 7.08%, contrasting with a slight 0.14% rise in the benchmark index. Year-to-date, the stock has plunged 26.78%, significantly underperforming the Sensex’s 8.37% gain. This underperformance extends to the one-year horizon, where the stock has lost 21.63% against the Sensex’s 3.59% appreciation.

On 16-Dec, the stock hit a new 52-week low of ₹2,103.05, underscoring the persistent selling pressure. It has also underperformed its sector by 1.17% on the day and has been declining for two consecutive sessions, losing 3.36% in that period. Technical indicators reveal that Mankind Pharma is trading below all key moving averages – 5-day, 20-day, 50-day, 100-day, and 200-day – signalling a bearish trend.

Interestingly, investor participation has increased, with delivery volumes rising by 39.34% to 5.48 lakh shares on 15 Dec compared to the five-day average. This heightened activity suggests that while selling pressure dominates, there is notable trading interest, possibly from institutional investors or traders repositioning amid the decline.

Fundamental Challenges Weighing on the Stock

Despite some positive attributes such as a high management efficiency reflected in a robust Return on Capital Employed (ROCE) of 25.78% and a strong debt servicing capability with a low Debt to EBITDA ratio of 0.54 times, the company’s recent financial results have disappointed investors. The latest half-yearly ROCE has dropped to 12.33%, signalling a weakening in capital efficiency.

Profitability metrics have also deteriorated. The company’s Profit After Tax (PAT) for the latest six months stood at ₹949.83 crore, marking a decline of 20.05%. Meanwhile, interest expenses for the nine months ended September 2025 surged by 122.24% to ₹530.87 crore, indicating rising financial costs that could be pressuring margins.

Valuation concerns further compound the negative sentiment. Mankind Pharma’s ROCE of 11.7 and an enterprise value to capital employed ratio of 4.5 suggest the stock is trading at a premium relative to its peers’ historical averages. This expensive valuation is difficult to justify given the recent profit decline and subdued growth prospects.

Over the past year, the stock’s return of -21.63% coincides with a 17.2% fall in profits, highlighting the disconnect between price performance and earnings. Additionally, the stock has underperformed the broader BSE500 index over multiple time frames, including the last three years, one year, and three months, reflecting persistent challenges in delivering shareholder value.

Investor Sentiment and Outlook

The combination of flat recent results, rising interest costs, declining profitability, and a stretched valuation has led to a cautious stance among investors. Institutional holdings remain relatively high at 24.76%, indicating that sophisticated investors continue to monitor the stock closely, but the negative earnings trajectory and technical weakness have likely prompted profit-taking and reduced buying interest.

Given the stock’s consistent underperformance against benchmarks and peers, alongside deteriorating fundamentals, the current price decline appears to be a market correction reflecting these underlying concerns. Until the company demonstrates a sustainable turnaround in earnings growth and valuation metrics normalise, the downward pressure on Mankind Pharma’s shares may persist.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →